Generation of EPO-producing MSCs by genetic engineering has been reported to enhance the benefits of MSC-based treatments in cardiovascular disease by improving their promotion of the angiogenic response and survival potential via endocrine and autocrine mechanisms, respectively [45]. The gene discussed is EPO; the disease is cardiovascular disorder.